Leerink Partners analyst Mani Foroohar has maintained their bullish stance on CRSP stock, giving a Buy rating on January 13.Stay Ahead of the ...

The most recent trading session ended with CRISPR Therapeutics AG (CRSP) standing at $38.36, reflecting a -1.26% shift from the previouse trading day's closing. The stock trailed the S&P 500, which ...

Crispr Therapeutics AG (CRSP) stock saw a decline, ending the day at $38.85 which represents a decrease of $-0.84 or -2.12% from the prior close of $39.69. The stock opened at $39.06 and touched a low ...

Researchers at the Broad Institute of MIT and Harvard have developed a gene-editing treatment for prion disease that extends ...

The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...

If we assume all patients who began treatment with Casgevy last year progress to the administration stage, CRISPR and Vertex ...

Synthego granted global license to manufacture and distribute AZ's CRISPR gene editing enzyme, eSpOT-ON.

From AI to gene therapy, we reached out to industry experts to get their thoughts on the trends that will shape the biotech ...

Ongoing launch of CASGEVY® continues to gain momentum--2025 is poised to be a catalyst-rich year with key updates across several ...

ON CRISPR enzyme, will combine with RNA guides for pharma customers. Deal follows HuidaGene agreement, offers 99% cost ...

Lehigh University bioenginering researcher Tomas Gonzalez-Fernandez recently secured funding through the National Science ...